Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Simultaneous Administration of RSV Preventive Monoclonal Antibody With Routine Childhood Immunizations in Infants
NCT07158814Phase 4Recruiting
- Sponsor
- Duke University
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nirsevimab in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Duke University. Primary endpoint: Number of Participants with Fever Following Immunization up to 2 days. Started Oct 2025; status: recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07158814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158814.